- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 18.09. | Radiopharm Theranostics Ltd - 20-F, Annual and transition report of foreign private issuers | - | SEC Filings | ||
| 17.09. | RADIOPHARM THERANOSTICS LIMITED: Corporate Governance Statement and Appendix 4G | - | ASX | ||
| 17.09. | RADIOPHARM THERANOSTICS LIMITED: Annual Report and Form 20-F | - | ASX | ||
| 15.09. | Radiopharm Theranostics Ltd - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 15.09. | RADIOPHARM THERANOSTICS LIMITED: Pivalate (Brain Mets) key opinion leader webinar | - | ASX | ||
| 29.08. | Radiopharm Theranostics Ltd - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 29.08. | RADIOPHARM THERANOSTICS LIMITED: Appendix 4E and Preliminary Final Report | - | ASX | ||
| 21.08. | Radiopharm Theranostics Ltd - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| RADIOPHARM THERANOSTICS Aktie jetzt für 0€ handeln | |||||
| 21.08. | RADIOPHARM THERANOSTICS LIMITED: Radiopharm to host key opinion leader webinar series | - | ASX | ||
| 01.08. | RADIOPHARM THERANOSTICS LIMITED: Notification regarding unquoted securities - RAD | 1 | ASX | ||
| 29.07. | Radiopharm Theranostics reports Fiscal Year 2025 Financial Results and Business Update | 376 | GlobeNewswire (Europe) | On track to complete enrollment of first two cohorts of RAD204 following positive recommendation from DSMC to escalate dose to 60mCi of Lu177 On track to complete enrollment of the first cohort of... ► Artikel lesen | |
| 29.07. | RADIOPHARM THERANOSTICS LIMITED: Quarterly Activities/Appendix 4C Cash Flow Report | - | ASX | ||
| 28.07. | FDA clears Radiopharm's IND application for Lu177-B7H3 antibody | 1 | Investing.com | ||
| 28.07. | Radiopharm Reports FDA Clearance To Initiate First-in-human Phase 1 Trial Of RV-01 | 1 | RTTNews | ||
| 28.07. | Radiopharm Theranostics erhält IND-Zulassung der FDA für Betabart (RV-01) | 1 | Investing.com Deutsch | ||
| 28.07. | Radiopharm Theranostics Ltd - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 28.07. | Radiopharm Theranostics Receives FDA Investigational New Drug Clearance for RV-01 Cancer Therapy | 1 | smallcaps.com.au | ||
| 28.07. | RADIOPHARM THERANOSTICS LIMITED: RAD receives IND approval from US FDA for Betabart (RV-01) | 3 | ASX | ||
| 22.07. | Radiopharm Theranostics: Dr Oliver Sartor Appointed to Radiopharm Scientific Advisory Board | 1 | GlobeNewswire (USA) | ||
| 21.07. | RADIOPHARM THERANOSTICS LIMITED: Dr Oliver Sartor appointed to RAD Scientific Advisory Board | - | ASX |
1 2 3 Weiter >>
43 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 37,515 | -0,35 % | BERENBERG stuft QIAGEN NV auf 'Buy' | HAMBURG (dpa-AFX Analyser) - Die Privatbank Berenberg hat die Einstufung für Qiagen mit einem Kursziel von 50 Euro auf "Buy" belassen. Der Diagnostikspezialist liege mit seinen Innovationen im Bereich... ► Artikel lesen | |
| BIONTECH | 83,90 | +0,06 % | BioNTech SE: BioNTech veranstaltet am 1. Oktober 2025 zweiten "AI Day" als eine Ausgabe der "Innovation Series" | MAINZ, Deutschland, 23. September 2025("InstaDeep"), am Dienstag, den 1. Oktober 2025 um 15:00 Uhr MESZ (09:00 Uhr EDT) ihren zweiten "AI Day" aus, eine Ausgabe von BioNTechs "Innovation Series"... ► Artikel lesen | |
| BIOAFFINITY TECHNOLOGIES | 5,280 | +54,84 % | Bioaffinity Technologies stock soars after lung cancer test aids early detection | ||
| RECURSION PHARMACEUTICALS | 4,725 | +2,05 % | Looking for the Next Big Pop? Here's Why Recursion Pharmaceuticals (RXRX) Could Do a Dead-Cat Bounce | ||
| EVOTEC | 5,932 | -1,76 % | AJN Resources, TUI, Evotec: Frisches Kapital und Insiderkäufe! | Frisches Kapital, Insiderkäufe oder wichtige Veränderungen im Aktionärskreis können wichtige Signale in Bezug auf die zukünftige Aktienkursentwicklung geben. Gerade bei kleineren Unternehmen ist der... ► Artikel lesen | |
| BEAM THERAPEUTICS | 22,980 | -0,48 % | Beam Therapeutics Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to BEAM-101 for the Treatment of Sickle Cell Disease | CAMBRIDGE, Mass., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 20,970 | +3,50 % | Summit Therapeutics: HARMONi-6, Featuring Ivonescimab Combined with Chemotherapy vs. Tislelizumab Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in China, to be Showcased in Presidential Symposium at ESMO 2025 | Ivonescimab in Combination with Chemotherapy in HARMONi-6, Conducted by Akeso in China, is the First Known Regimen to Achieve a Statistically Significant Clinically Meaningful Improvement in PFS... ► Artikel lesen | |
| INDAPTUS THERAPEUTICS | 3,490 | +6,40 % | Indaptus Therapeutics Provides Clinical Update | Decoy20 monotherapy induces Partial Response in patient with urothelial cancer and liver metastases Decoy20 combination with PD-1 inhibitor, tislelizumab, demonstrates safety profiles consistent with... ► Artikel lesen | |
| KYMERA THERAPEUTICS | 56,29 | +4,65 % | Kymera Therapeutics, Inc.: Kymera Therapeutics Appoints Brian Adams as Chief Legal Officer and Corporate Secretary | WATERTOWN, Mass., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines... ► Artikel lesen | |
| 89BIO | 14,700 | 0,00 % | Roche To Buy 89bio For Up To $3.5 Billion | ||
| AVIDITY BIOSCIENCES | 42,880 | +4,97 % | Avidity Biosciences, Inc.: Avidity Biosciences Reports Second Quarter 2025 Financial Results and Recent Highlights | Aligned with FDA on del-brax accelerated and full approval pathways for FSHD, reported positive topline data from Phase 1/2 FORTITUDE trial, and initiated global... ► Artikel lesen | |
| MINERALYS THERAPEUTICS | 39,985 | +3,83 % | Mineralys Therapeutics, Inc.: Mineralys Therapeutics Announces Late-Breaking Presentation of Data from the Launch-HTN Pivotal Trial of Lorundrostat in Uncontrolled or Resistant Hypertension at 34th European Meeting on Hypertension ... | - Largest hypertension trial of an aldosterone synthase inhibitor to date demonstrated the efficacy of lorundrostat in over 1,000 participants with uncontrolled or resistant hypertension in a real-world... ► Artikel lesen | |
| ARRIVENT BIOPHARMA | 18,030 | +5,01 % | ArriVent BioPharma, Inc.: ArriVent Appoints Brent S. Rice as Chief Commercial Officer | NEWTOWN SQUARE, Pa., Sept. 22, 2025 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of... ► Artikel lesen | |
| MOONLAKE IMMUNOTHERAPEUTICS | 61,93 | +9,84 % | MoonLake Immunotherapeutics AG: MoonLake Immunotherapeutics Reports Second Quarter 2025 Financial Results and Provides a Business Update | Phase 3 VELA program in hidradenitis suppurativa (HS) on track for an expected primary endpoint readout around September 2025 and an expected submission of a Biologic License Application (BLA) in the... ► Artikel lesen | |
| MBX BIOSCIENCES | 17,535 | +1,18 % | MBX Biosciences, Inc.: MBX Biosciences Announces Pricing of Upsized Public Offering | CARMEL, Ind., Sept. 24, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide... ► Artikel lesen |
RADIOPHARM THERANOSTICS LIMITED ADR gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell -2,95 % bei einem Aktienkurs von 5,600 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu RADIOPHARM THERANOSTICS LIMITED ADR finden Sie auf Wallstreet Online.